Company / Shareholders' Equity
SELLAS Life Sciences Group, Inc. Shareholders' Equity History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$9.5M
FY2024
5-year range
-$8.0M / $28.0M
FY2020-FY2024
Trend
+218.7%
vs FY2023
Sector context
#189 of 213
Health Care
What the data says
Shareholders' Equity changed +219% YoY in FY2024, a notable deviation from the 9-year average annual change of +87%.
Based on SEC 10-K filings.
$9M in FY2024 with a 5-year CAGR of +9.2%.
Declined from $20M to $9M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -30.3%
- 5-Year CAGR
- +9.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 213This company $9.5M Sector average $2.5B
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.2%, indicating consistent growth.
- In FY2024, shareholders' equity increased 218.7% year-over-year.
- Ranks #189 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $9.5M | +218.7% |
| FY2023 | -$8.0M | -139.2% |
| FY2022 | $20.3M | -27.2% |
| FY2021 | $28.0M | +0.0% |
| FY2020 | $28.0M | +358.9% |
| FY2019 | $6.1M | +16.2% |
| FY2018 | $5.2M | +153.4% |
| FY2017 | $2.1M | +141.4% |
| FY2016 | -$5.0M | +59.2% |
| FY2015 | -$12.3M | -133.1% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026